PSP-0119

• Description:

  PSP-0119 is a highly efficient and effective PROTAC degrader targeting IRAK4 (IC50 = 2.83 nM) . PSP-0119 can inhibit IRAK4 kinase activity, NF-κβ activity, and IL-1β-induced IRAK4 phosphorylation. PSP-0119 degrades IRAK4 in FLT3-mutant AML cell lines, sparing FLT3-wild-type AML cells, FLT3-wild-type samples, and normal bone marrow. PSP-0119 downregulates alpha-enolase (eNOS) of MOLM-13 cells. PSP-0119 can be used for the study of Acute Myeloid Leukemia (AML) [1].

• UNSPSC:

  12352005

• Target:

  Enolase; IRAK; NF-κB; PROTACs

• Related Pathways:

  Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; PROTAC

• Field of Research:

  Cancer; Inflammation/Immunology

• Smiles:

  COC1=CC(N2CCN(CC2)C(CCCC(NC3=CC=CC4=C3CN(C4=O)C5CCC(NC5=O)=O)=O)=O)=CC=C1NC(C6=CC=CC(C7=NNC=C7)=N6)=O

• Molecular Formula:

  C38H39N9O7

• Molecular Weight:

  733.77

• References & Citations:

  [1]Khazan N, et al. PSP-0119: Targeted IRAK4 Degradation as a Novel Therapeutic Strategy for FLT3-Mutant AML. bioRxiv [Preprint]. 2025 Oct 2:2025.09.30.679569.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  IRAK4; NF-κB